ALX Oncology is prioritizing evorpacept development in combination with anti-cancer antibodies that directly induce antibody-dependent cellular phagocytosis (ADCP), the primary proposed mechanism of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback